ANI PHARMACEUTICALS, INC Cost of Revenue
ANI PHARMACEUTICALS, INC (ANIP) reported Cost of Revenue of $19.98 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2021-05-07
- ANI PHARMACEUTICALS, INC cost of revenue for the quarter ending 2021-03-31 was $19.98M, a 8.34% decline year-over-year.
- ANI PHARMACEUTICALS, INC cost of revenue for the quarter ending 2020-12-31 was $24.54M, a 37.90% increase year-over-year.
- ANI PHARMACEUTICALS, INC cost of revenue for the quarter ending 2020-09-30 was $20.12M, a 34.10% increase year-over-year.
- ANI PHARMACEUTICALS, INC cost of revenue for the quarter ending 2020-06-30 was $20.70M, a 32.39% increase year-over-year.
- ANI PHARMACEUTICALS, INC cost of revenue for fiscal 2020 was $87.16M, a 38.01% increase from fiscal 2019.
- ANI PHARMACEUTICALS, INC cost of revenue for fiscal 2019 was $63.15M, a 13.52% decline from fiscal 2018.
- ANI PHARMACEUTICALS, INC cost of revenue for fiscal 2018 was $73.02M, a 7.60% decline from fiscal 2017.
- ANI PHARMACEUTICALS, INC cost of revenue for fiscal 2017 was $79.03M, a 62.02% increase from fiscal 2016.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month |
|---|---|---|---|---|---|---|---|
| 2021-03-31 | $19.98M 10-Q · filed 2021-05-07 | $44.52M derived: sum of 2 quarters · filed 2021-05-07 | $64.64M derived: sum of 3 quarters · filed 2021-05-07 | $85.34M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2020-12-31 | $24.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $44.66M derived: sum of 2 quarters · filed 2021-03-11 | $65.35M derived: sum of 3 quarters · filed 2021-03-11 | $87.16M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $20.12M 10-Q · filed 2020-11-05 | $40.81M derived: sum of 2 quarters · filed 2020-11-05 | $62.62M 10-Q · filed 2020-11-05 | $80.41M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2020-06-30 | $20.70M 10-Q · filed 2020-08-06 | $42.50M 10-Q · filed 2020-08-06 | $60.29M derived: sum of 3 quarters · filed 2021-05-07 | $75.30M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2020-03-31 | $21.80M 10-Q · filed 2021-05-07 | $39.60M derived: sum of 2 quarters · filed 2021-05-07 | $54.60M derived: sum of 3 quarters · filed 2021-05-07 | $70.23M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $17.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $32.80M derived: sum of 2 quarters · filed 2021-03-11 | $48.43M derived: sum of 3 quarters · filed 2021-03-11 | $63.15M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $15.00M 10-Q · filed 2020-11-05 | $30.63M derived: sum of 2 quarters · filed 2020-11-05 | $45.36M 10-Q · filed 2020-11-05 | $65.49M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2019-06-30 | $15.63M 10-Q · filed 2020-08-06 | $30.36M 10-Q · filed 2020-08-06 | $50.49M derived: sum of 3 quarters · filed 2021-03-11 | $66.09M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2019-03-31 | $14.72M 10-Q · filed 2020-05-07 | $34.86M derived: sum of 2 quarters · filed 2021-03-11 | $50.46M derived: sum of 3 quarters · filed 2021-03-11 | $67.06M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-12-31 | $20.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $35.74M derived: sum of 2 quarters · filed 2021-03-11 | $52.33M derived: sum of 3 quarters · filed 2021-03-11 | $73.02M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $15.61M 10-Q · filed 2019-11-06 | $32.20M derived: sum of 2 quarters · filed 2019-11-06 | $52.89M 10-Q · filed 2019-11-06 | $73.34M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $16.59M 10-Q · filed 2019-08-07 | $37.29M 10-Q · filed 2019-08-07 | $57.73M derived: sum of 3 quarters · filed 2020-02-27 | $78.81M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | $20.69M 10-Q · filed 2019-05-09 | $41.14M derived: sum of 2 quarters · filed 2020-02-27 | $62.22M derived: sum of 3 quarters · filed 2020-02-27 | $83.34M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $20.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $41.52M derived: sum of 2 quarters · filed 2020-02-27 | $62.65M derived: sum of 3 quarters · filed 2020-02-27 | $79.03M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $21.08M 10-Q · filed 2018-11-06 | $42.20M derived: sum of 2 quarters · filed 2018-11-06 | $58.59M 10-Q · filed 2018-11-06 | $75.49M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-06-30 | $21.12M 10-Q · filed 2017-08-03 | $37.51M 10-Q · filed 2018-08-07 | $54.41M derived: sum of 3 quarters · filed 2019-02-27 | $71.08M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-03-31 | $16.39M 10-Q · filed 2018-05-08 | $33.29M derived: sum of 2 quarters · filed 2019-02-27 | $49.96M derived: sum of 3 quarters · filed 2019-02-27 | $61.76M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2016-12-31 | $16.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $33.58M derived: sum of 2 quarters · filed 2019-02-27 | $45.37M derived: sum of 3 quarters · filed 2019-02-27 | $48.78M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $16.67M 10-Q · filed 2017-11-02 | $28.46M derived: sum of 2 quarters · filed 2017-11-02 | $31.87M 10-Q · filed 2017-11-02 | $35.41M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $11.79M 10-Q · filed 2017-08-03 | $15.21M 10-Q · filed 2017-08-03 | $18.75M derived: sum of 3 quarters · filed 2018-02-27 | $22.00M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $3.41M 10-Q · filed 2017-05-04 | $6.95M derived: sum of 2 quarters · filed 2018-02-27 | $10.21M derived: sum of 3 quarters · filed 2018-02-27 | $13.35M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $6.80M derived: sum of 2 quarters · filed 2018-02-27 | $9.94M derived: sum of 3 quarters · filed 2018-02-27 | $12.69M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $3.26M 10-Q · filed 2016-11-03 | $6.40M derived: sum of 2 quarters · filed 2016-11-03 | $9.15M 10-Q · filed 2016-11-03 | $12.82M derived: sum of 4 quarters · filed 2017-03-02 | |||
| 2015-06-30 | $3.14M 10-Q · filed 2016-08-04 | $5.89M 10-Q · filed 2016-08-04 | $9.56M derived: sum of 3 quarters · filed 2017-03-02 | $12.63M derived: sum of 4 quarters · filed 2017-03-02 | |||
| 2015-03-31 | $2.75M 10-Q · filed 2016-05-05 | $6.42M derived: sum of 2 quarters · filed 2017-03-02 | $9.48M derived: sum of 3 quarters · filed 2017-03-02 | $11.60M derived: sum of 4 quarters · filed 2017-03-02 | |||
| 2014-12-31 | $3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $6.73M derived: sum of 2 quarters · filed 2017-03-02 | $8.85M derived: sum of 3 quarters · filed 2017-03-02 | $11.47M 10-K · filed 2017-03-02 | |||
| 2014-09-30 | $3.06M 10-Q · filed 2015-11-03 | $5.18M derived: sum of 2 quarters · filed 2015-11-03 | $7.80M 10-Q · filed 2015-11-03 | $10.48M derived: sum of 4 quarters · filed 2016-02-23 | |||
| 2014-06-30 | $2.12M 10-Q · filed 2015-08-04 | $4.74M 10-Q · filed 2015-08-04 | $7.42M derived: sum of 3 quarters · filed 2016-02-23 | $10.13M derived: sum of 4 quarters · filed 2016-02-23 | |||
| 2014-03-31 | $2.62M 10-Q · filed 2015-05-05 | $5.31M derived: sum of 2 quarters · filed 2016-02-23 | $8.02M derived: sum of 3 quarters · filed 2016-02-23 | $10.19M derived: sum of 4 quarters · filed 2016-02-23 | |||
| 2013-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $5.39M derived: sum of 2 quarters · filed 2016-02-23 | $7.57M derived: sum of 3 quarters · filed 2016-02-23 | $9.97M 10-K · filed 2016-02-23 | |||
| 2013-09-30 | $2.71M 10-Q · filed 2014-11-10 | $2.63M 10-Q · filed 2013-11-07 | $4.88M derived: sum of 2 quarters · filed 2014-11-10 | $7.29M 10-Q · filed 2014-11-10 | $7.07M 10-Q · filed 2013-11-07 | $10.16M derived: sum of 4 quarters · filed 2014-11-10 | |
| 2013-06-30 | $2.17M 10-Q · filed 2014-08-07 | $2.10M 10-Q · filed 2013-08-09 | $4.58M 10-Q · filed 2014-08-07 | $4.44M 10-Q · filed 2013-08-09 | $7.45M derived: sum of 3 quarters · filed 2014-08-07 | $9.78M derived: sum of 4 quarters · filed 2014-08-07 | |
| 2013-03-31 | $2.41M 10-Q · filed 2014-05-12 | $5.28M derived: sum of 2 quarters · filed 2014-05-12 | $7.60M derived: sum of 3 quarters · filed 2014-05-12 | $9.72M derived: sum of 4 quarters · filed 2014-05-12 | |||
| 2012-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $5.20M derived: sum of 2 quarters · filed 2014-02-28 | $7.32M derived: sum of 3 quarters · filed 2014-02-28 | $9.17M 10-K · filed 2014-02-28 | |||
| 2012-09-30 | $2.32M 10-Q · filed 2013-11-07 | $4.44M derived: sum of 2 quarters · filed 2013-11-07 | $6.29M 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $2.12M 10-Q · filed 2013-08-09 | $3.97M 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |